Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

Martin M. and Zielinski C. and Ruiz-Borrego M. and Carrasco E. and Turner N. and Ciruelos E. M. and Muñoz M. and Bermejo B. and Margeli M. and Anton A. and Kahán Zsuzsanna and Csöszi Tibor and Casas M. I. and Murillo L. and Morales S.: Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL.
ANNALS OF ONCOLOGY, 32 (4). pp. 488-499. ISSN 0923-7534 (2021)

[thumbnail of 1-s2.0-S0923753420432211-main.pdf]
Preview
Text
1-s2.0-S0923753420432211-main.pdf - Published Version

Download (541kB) | Preview
Creators:
Martin M.
Zielinski C.
Ruiz-Borrego M.
Carrasco E.
Turner N.
Ciruelos E. M.
Muñoz M.
Bermejo B.
Margeli M.
Anton A.
Kahán Zsuzsanna MTMT
Csöszi Tibor
Casas M. I.
Murillo L.
Morales S.
Item Type: Journal Article
Szerzők száma: 33
Journal or Publication Title: ANNALS OF ONCOLOGY
Date: 2021
Volume: 32
Number: 4
Page Range: pp. 488-499
ISSN: 0923-7534
Faculty/Unit: Albert Szent-Györgyi Medical School
Institution: University of Szeged (2000-)
Language: English
MTMT rekordazonosító: 32546756
DOI azonosító: https://doi.org/10.1016/j.annonc.2020.12.013
Date Deposited: 2022. Jan. 04. 09:35
Last Modified: 2022. Jan. 04. 09:35
URI: http://publicatio.bibl.u-szeged.hu/id/eprint/23111
Web of Science® Times Cited: 89 View citing articles in Web of Science®

Actions (login required)

View Item View Item